71 related articles for article (PubMed ID: 31845224)
1. DCLK1 Expression and its Functional Significance in Intrahepatic Cholangiocarcinoma and Bil-IN Stage.
Fukushima NM; Adachi T; Tanaka T; Matsushima H; Imamura H; Hara T; Soyama A; Hidaka M; Kanetaka K; Eguchi S
Anticancer Res; 2024 Jun; 44(6):2417-2424. PubMed ID: 38821583
[TBL] [Abstract][Full Text] [Related]
2. FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma.
Shihadih D; Wang X; Zushin PH; Khodakivskyi P; Park HM; Tso E; Shiblak J; Misic A; Louie SM; Ward C; Hellerstein M; Nomura DK; Goun E; Urigo F; Calvisi DF; Chen X; Stahl A
Mol Cancer Res; 2024 Jun; 22(6):585-595. PubMed ID: 38358323
[TBL] [Abstract][Full Text] [Related]
3. UBA3 promotes the occurrence and metastasis of intrahepatic cholangiocarcinoma through MAPK signaling pathway.
Zhang H; Yang J; Song Q; Ding X; Sun F; Yang L
Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):199-209. PubMed ID: 38298057
[TBL] [Abstract][Full Text] [Related]
4. SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma.
Luk IS; Bridgwater CM; Yu A; Boila LD; Yáñez-Bartolomé M; Lampano AE; Hulahan TS; Boukhali M; Kathiresan M; Macarulla T; Kenerson HL; Yamamoto N; Sokolov D; Engstrom IA; Sullivan LB; Lampe PD; Cooper JA; Yeung RS; Tian TV; Haas W; Saha SK; Kugel S
Sci Transl Med; 2024 May; 16(747):eadj7685. PubMed ID: 38748774
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiota regulates the ALK5/NOX1 axis by altering glutamine metabolism to inhibit ferroptosis of intrahepatic cholangiocarcinoma cells.
Zhang Q; Zhou J; Zhai D; Jiang Q; Yang M; Zhou M
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167152. PubMed ID: 38582012
[TBL] [Abstract][Full Text] [Related]
6. Escherichia coli-Induced cGLIS3-Mediated Stress Granules Activate the NF-κB Pathway to Promote Intrahepatic Cholangiocarcinoma Progression.
Kang FP; Chen ZW; Liao CY; Wu YD; Li G; Xie CK; Lin HY; Huang L; Tian YF; Wang ZW; Chen S
Adv Sci (Weinh); 2024 Apr; 11(16):e2306174. PubMed ID: 38368261
[TBL] [Abstract][Full Text] [Related]
7. Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
Banales JM; Marin JJG; Lamarca A; Rodrigues PM; Khan SA; Roberts LR; Cardinale V; Carpino G; Andersen JB; Braconi C; Calvisi DF; Perugorria MJ; Fabris L; Boulter L; Macias RIR; Gaudio E; Alvaro D; Gradilone SA; Strazzabosco M; Marzioni M; Coulouarn C; Fouassier L; Raggi C; Invernizzi P; Mertens JC; Moncsek A; Rizvi S; Heimbach J; Koerkamp BG; Bruix J; Forner A; Bridgewater J; Valle JW; Gores GJ
Nat Rev Gastroenterol Hepatol; 2020 Sep; 17(9):557-588. PubMed ID: 32606456
[TBL] [Abstract][Full Text] [Related]
8. Notch1 in Cancer Therapy: Possible Clinical Implications and Challenges.
Gharaibeh L; Elmadany N; Alwosaibai K; Alshaer W
Mol Pharmacol; 2020 Nov; 98(5):559-576. PubMed ID: 32913140
[TBL] [Abstract][Full Text] [Related]
9. The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.
Ma W; Han C; Zhang J; Song K; Chen W; Kwon H; Wu T
Hepatology; 2020 Oct; 72(4):1283-1297. PubMed ID: 31990985
[TBL] [Abstract][Full Text] [Related]
10. NOTCH signalling - a core regulator of bile duct disease?
Martinez Lyons A; Boulter L
Dis Model Mech; 2023 Sep; 16(9):. PubMed ID: 37605966
[TBL] [Abstract][Full Text] [Related]
11. Hydrodynamic Delivery: Characteristics, Applications, and Technological Advances.
Suda T; Yokoo T; Kanefuji T; Kamimura K; Zhang G; Liu D
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111597
[TBL] [Abstract][Full Text] [Related]
12. Atractylodin and β-eudesmol from Atractylodes lancea (Thunb.) DC. Inhibit Cholangiocarcinoma Cell Proliferation by Downregulating the Notch Signaling Pathway.
Vanaroj P; Chaijaroenkul W; Na-Bangchang K
Asian Pac J Cancer Prev; 2023 Feb; 24(2):551-558. PubMed ID: 36853304
[TBL] [Abstract][Full Text] [Related]
13. Update on Hepatobiliary Plasticity.
Kim M; Rizvi F; Shin D; Gouon-Evans V
Semin Liver Dis; 2023 Feb; 43(1):13-23. PubMed ID: 36764306
[TBL] [Abstract][Full Text] [Related]
14. Selecting an Appropriate Experimental Animal Model for Cholangiocarcinoma Research.
Li M; Zhou X; Wang W; Ji B; Shao Y; Du Q; Yao J; Yang Y
J Clin Transl Hepatol; 2022 Aug; 10(4):700-710. PubMed ID: 36062286
[TBL] [Abstract][Full Text] [Related]
15. Hes1 Controls Proliferation and Apoptosis in Chronic Lymphoblastic Leukemia Cells by Modulating PTEN Expression.
Zhang Q; Zhu Z; Guan J; Hu Y; Zhou W; Ye W; Lin B; Weng S; Chen Y; Zheng C
Mol Biotechnol; 2022 Dec; 64(12):1419-1430. PubMed ID: 35704163
[TBL] [Abstract][Full Text] [Related]
16. The Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression.
Mancarella S; Serino G; Coletta S; Armentano R; Dituri F; Ardito F; Ruzzenente A; Fabregat I; Giannelli G
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457006
[TBL] [Abstract][Full Text] [Related]
17. Role of Notch Receptors in Hematologic Malignancies.
Gragnani L; Lorini S; Marri S; Zignego AL
Cells; 2020 Dec; 10(1):. PubMed ID: 33374160
[TBL] [Abstract][Full Text] [Related]
18. Notch1 Drives the Formation and Proliferation of Intrahepatic Cholangiocarcinoma.
Guo J; Fu W; Xiang M; Zhang Y; Zhou K; Xu CR; Li L; Kuang D; Ye F
Curr Med Sci; 2019 Dec; 39(6):929-937. PubMed ID: 31845224
[TBL] [Abstract][Full Text] [Related]
19. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
Wu WR; Zhang R; Shi XD; Zhu MS; Xu LB; Zeng H; Liu C
Oncol Rep; 2014 Jun; 31(6):2515-24. PubMed ID: 24700253
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
